Current State of Pediatric Heart Failure

Pediatric heart failure (HF) represents an important cause of morbidity and mortality in childhood. There is an overlapping relationship of HF, congenital heart disease, and cardiomyopathy. The goal of treatment of HF in children is to maintain stability, prevent progression, and provide a reasonabl...

Full description

Bibliographic Details
Main Author: Bibhuti B. Das
Format: Article
Language:English
Published: MDPI AG 2018-06-01
Series:Children
Subjects:
Online Access:http://www.mdpi.com/2227-9067/5/7/88
id doaj-b25e3fc8fabe48e994c32e897b39e390
record_format Article
spelling doaj-b25e3fc8fabe48e994c32e897b39e3902021-04-02T01:26:02ZengMDPI AGChildren2227-90672018-06-01578810.3390/children5070088children5070088Current State of Pediatric Heart FailureBibhuti B. Das0Joe DiMaggio Children’s Heart Institute, Memorial Health Care System, Hollywood, FL 33021, USAPediatric heart failure (HF) represents an important cause of morbidity and mortality in childhood. There is an overlapping relationship of HF, congenital heart disease, and cardiomyopathy. The goal of treatment of HF in children is to maintain stability, prevent progression, and provide a reasonable milieu to allow somatic growth and optimal development. Current management and therapy for HF in children are extrapolated from treatment approaches in adults. There are significant barriers in applying adult data to children because of developmental factors, age variation from birth to adolescence, and differences in the genetic expression profile and β-adrenergic signaling. At the same time, there are significant challenges in performing well-designed drug trials in children with HF because of heterogeneity of diagnoses identifying a clinically relevant outcome with a high event rate, and a difficulty in achieving sufficient enrollment. A judicious balance between extrapolation from adult HF guidelines and the development of child-specific data on treatment represent a wise approach to optimize pediatric HF management. This approach is helpful as reflected by the increasing role of ventricular assist devices in the management of advanced HF in children. This review discusses the causes, epidemiology, pathophysiology, clinical manifestations, conventional medical treatment, clinical trials, and the role of device therapy in pediatric HF.http://www.mdpi.com/2227-9067/5/7/88pediatric heart failureadvanced heart failureventricular assist devicemechanical circulatory support
collection DOAJ
language English
format Article
sources DOAJ
author Bibhuti B. Das
spellingShingle Bibhuti B. Das
Current State of Pediatric Heart Failure
Children
pediatric heart failure
advanced heart failure
ventricular assist device
mechanical circulatory support
author_facet Bibhuti B. Das
author_sort Bibhuti B. Das
title Current State of Pediatric Heart Failure
title_short Current State of Pediatric Heart Failure
title_full Current State of Pediatric Heart Failure
title_fullStr Current State of Pediatric Heart Failure
title_full_unstemmed Current State of Pediatric Heart Failure
title_sort current state of pediatric heart failure
publisher MDPI AG
series Children
issn 2227-9067
publishDate 2018-06-01
description Pediatric heart failure (HF) represents an important cause of morbidity and mortality in childhood. There is an overlapping relationship of HF, congenital heart disease, and cardiomyopathy. The goal of treatment of HF in children is to maintain stability, prevent progression, and provide a reasonable milieu to allow somatic growth and optimal development. Current management and therapy for HF in children are extrapolated from treatment approaches in adults. There are significant barriers in applying adult data to children because of developmental factors, age variation from birth to adolescence, and differences in the genetic expression profile and β-adrenergic signaling. At the same time, there are significant challenges in performing well-designed drug trials in children with HF because of heterogeneity of diagnoses identifying a clinically relevant outcome with a high event rate, and a difficulty in achieving sufficient enrollment. A judicious balance between extrapolation from adult HF guidelines and the development of child-specific data on treatment represent a wise approach to optimize pediatric HF management. This approach is helpful as reflected by the increasing role of ventricular assist devices in the management of advanced HF in children. This review discusses the causes, epidemiology, pathophysiology, clinical manifestations, conventional medical treatment, clinical trials, and the role of device therapy in pediatric HF.
topic pediatric heart failure
advanced heart failure
ventricular assist device
mechanical circulatory support
url http://www.mdpi.com/2227-9067/5/7/88
work_keys_str_mv AT bibhutibdas currentstateofpediatricheartfailure
_version_ 1724175227475197952